RBC8

RBC8 is a selective and allosteric RALA and RALB inhibitor. RBC8 stabilizes the inactive GDP-bound state of Ral, preventing its activation. RBC8 promotes the phosphorylation of proteins related to the MAPK/JNK pathway. RBC8 has the activity of inhibiting tumor cell proliferation, migration and invasion. RBC8 is used in the study of various cancers such as lung cancer, gastric cancer, and multiple myeloma[1][2][3].

Product Specifications

CAS Number

[361185-42-4]

UNSPSC

12352005

Hazard Statement

H302

Target

JNK; p38 MAPK; Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/RBC8.html

Purity

98.0

Solubility

DMSO : ≥ 40 mg/mL

Smiles

N#CC(C1C2=CC(OC)=CC=C2OC)=C(N)OC3=C1C(C4=CC=C5C=CC=CC5=C4)=NN3

Molecular Formula

C25H20N4O3

Molecular Weight

424.45

Precautions

H302

References & Citations

[1]Yan C, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515 (7527) :443-7.|[2]Seibold M, et al. RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica. 2020 Sep 1;105 (9) :2316-2326.|[3]Wang P, et al. RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer. Onco Targets Ther. 2020 Apr 14;13:3093-3103.